Glaxo, Eon Settle Wellbutrin Patent Dispute

Law360, New York (April 28, 2004, 12:00 AM EDT) -- Drug maker GlaxoSmithKline PLC and generic pharmaceutical company Eon Labs Inc. have settled all patent litigation regarding Eon's Bupropion HCl, ER 100 mg and 10 mg tablets, the two companies said.

Eon's Bupropion drug is the generic equivalent of GlaxoSmithKline's Wellbutrin (bupropion HCl extended- release).

Under terms of the settlement, GlaxoSmithKline has agreed to drop any further effort to pursue its claim that Bupropion HCl, ER 100 mg and 150 mg tablets infringe its patents.

On Nov. 26, the Food and Drug Administration approved Eon’s tablet...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.